Senior Postdoctoral Researcher
Identifying and advancing novel molecular targets of interest to psychiatry
I am a Senior Postdoctoral Researcher in psychiatric therapeutic neuroscience. I am a biochemist/molecular biologist by training with broad research experience in the analysis of gene regulation and signalling in development and disease.
Rapidly evolving large-scale genomic studies offer a window into the molecular and cellular pathways that confer risk for psychiatric disorders with the potential to transform our understanding of the biology underlying these illnesses. However, this plethora of genomic data must be triaged to identify the most promising candidates for new drug targets.
By integrating data from a variety of sources (e.g. genomic data, open-access datasets, and scientific literature) my research involves identifying and prioritising molecular targets that may be relevant to the treatment and/or pathogenesis of psychiatric disorders.
Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia.
Mould AW. et al, (2022), CNS Drugs, 36, 1 - 16
The transcriptional repressor Blimp1/PRDM1 regulates the maternal decidual response in mice.
Goolam M. et al, (2020), Nat Commun, 11
Cellular calcium in bipolar disorder: systematic review and meta-analysis.
Harrison PJ. et al, (2019), Mol Psychiatry
The Oxford study of Calcium channel Antagonism, Cognition, Mood instability and Sleep (OxCaMS): study protocol for a randomised controlled, experimental medicine study.
Atkinson LZ. et al, (2019), Trials, 20
Publisher Correction: Single-cell RNA-seq reveals cell type-specific transcriptional signatures at the maternal-foetal interface during pregnancy.
Nelson AC. et al, (2018), Nat Commun, 9